Luo Meiyan, Zhang Qian, Hu Yingchun, Sun Changfeng, Sheng Yunjian, Deng Cunliang
Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Louzhou, 646000, People's Republic of China.
Department of Tuberculosis, The Affiliated Hospital of Southwest Medical University, Louzhou, 646000, People's Republic of China.
Infect Drug Resist. 2021 Jul 24;14:2863-2871. doi: 10.2147/IDR.S316402. eCollection 2021.
This study aimed to screen differentially expressed proteins (DEPs) in plasma of patients with sepsis through data-independent acquisition (DIA) and enzyme-linked immunosorbent assays (ELISAs), and provide convenient and accurate serum markers for determining the condition of septic patients.
A total of 53 septic patients and 16 normal controls who were admitted to the Affiliated Hospital of Southwest Medical University between January 2019 and December 2020 were enrolled in this study; 6 specimens from the normal group and 15 from the sepsis group were randomly selected for DIA-based quantitative proteomic analysis. The acquired data were subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and a protein-protein interaction (PPI) network was constructed to screen potential markers. The selected proteins were further verified through ELISAs. The differences between control and sepsis groups and between survivors and non-survivors were analysed. Receiver operating characteristic (ROC) curves were drawn to explore their diagnostic value and prognostic efficacy.
A total of 149 DEPs were identified by bioinformatics methods. The analyses showed that these proteins are mainly involved in biological processes such as cell movement, stress response, cell proliferation, and immune response. Functional pathway analysis showed that they are mainly involved in leukocyte transendothelial migration, protein synthesis and processing, and various bacterial infections. LGALS3BP was selected as a potential plasma biomarker and further verified through an ELISA. Its level in septic patients was significantly higher than that in normal controls, and its level in non-survivors was also higher than that in survivors. The ROC curves suggested its great diagnostic efficacy and prognostic ability in sepsis.
LGALS3BP levels were significantly different between the normal and sepsis groups; it has good diagnostic value in sepsis, and is related to patient prognosis; thus, it might be a biomarker for sepsis.
本研究旨在通过数据非依赖采集（DIA）和酶联免疫吸附测定（ELISA）筛选脓毒症患者血浆中差异表达蛋白（DEP），为判断脓毒症患者病情提供便捷、准确的血清标志物。
选取2019年1月至2020年12月在西南医科大学附属医院收治的53例脓毒症患者和16例正常对照；从正常组随机选取6份标本，脓毒症组随机选取15份标本进行基于DIA的定量蛋白质组学分析。对获取的数据进行基因本体论（GO）和京都基因与基因组百科全书（KEGG）分析，并构建蛋白质-蛋白质相互作用（PPI）网络以筛选潜在标志物。通过ELISA对所选蛋白质进行进一步验证。分析对照组与脓毒症组之间以及存活者与非存活者之间的差异。绘制受试者工作特征（ROC）曲线以探讨其诊断价值和预后效能。
通过生物信息学方法共鉴定出149个DEP。分析表明，这些蛋白质主要参与细胞运动、应激反应、细胞增殖和免疫反应等生物学过程。功能通路分析表明，它们主要参与白细胞跨内皮迁移、蛋白质合成与加工以及各种细菌感染。选择LGALS3BP作为潜在的血浆生物标志物，并通过ELISA进一步验证。其在脓毒症患者中的水平显著高于正常对照，在非存活者中的水平也高于存活者。ROC曲线表明其在脓毒症中具有良好的诊断效能和预后能力。
正常组与脓毒症组之间LGALS3BP水平存在显著差异；其在脓毒症中具有良好的诊断价值，并与患者预后相关；因此，它可能是脓毒症的一个生物标志物。
